FROM THE PIPELINE | A long-acting multipurpose prevention ring to help protect against HIV and unintended pregnancy

Tuesday, 13 March 2018

Leveraging its experience developing the first vaginal ring and long-acting product shown to help prevent HIV, the nonprofit International Partnership for Microbicides is now developing a three-month vaginal ring designed to reduce women’s HIV risk and prevent unplanned pregnancy. This innovative multipurpose prevention technology would offer women a discreet option to protect their sexual and reproductive health on their own terms.

“Young women are more worried about being pregnant. But HIV is dangerous. We need dual protection.” – Young woman at HIV prevention forum

Time and again, we at the International Partnership for Microbicides (IPM) hear women ask for MPTs they can use to protect their sexual and reproductive health.

It’s easy to see why: across the globe, a woman between the ages of 15 and 44 is most likely to die from causes related to HIV/AIDS or from complications related to pregnancy and childbirth[1]. And women often face dual risks, because areas with high rates of HIV also have high unmet contraceptive need. In Sub-Saharan Africa—where women carry nearly 60 percent of the HIV burden and young women are at least twice as likely to become infected as young men[2]—21 percent of women want, but lack access to, modern contraceptive methods[3].

Advancing new solutions: The dapivirine-contraceptive ring

Although existing MPTs like male and female condoms are highly effective when used, it’s not always possible for women to negotiate condom use with their partners. That’s why IPM is prioritizing the development of a new option that women could use discreetly: a three-month vaginal ring designed to offer simultaneous protection against HIV and unintended pregnancy.

Leveraging our experience developing a one-month HIV prevention vaginal ring, which has been clinically shown to safely help reduce women’s HIV risk, the MPT ring combines the antiretroviral drug dapivirine with the contraceptive hormone levonorgestrel. Women would insert the ring themselves and replace it every three months.

Last year, the dapivirine-contraceptive ring moved into its first clinical trial to assess the ring’s safety and pharmacokinetics, or how the body processes the two drugs, and to explore product acceptability. The study is being conducted by IPM’s partner, the Microbicide Trials Network, among 24 women at two sites in the United States. We expect to have results later in 2018, which will help us determine the next steps for the product’s development.

The dapivirine-contraceptive ring would be the first product of its kind, providing women with a self-initiated, long-acting dual-purpose prevention option they can control on their own terms. The more options women have, the more likely they are to find one they can use.

The promise of MPTs

A long-acting innovation like the dapivirine-contraceptive ring offers greater convenience, requires fewer clinic visits, and may reduce the stigma associated with HIV services because MPTs would likely be delivered through family planning services. MPTs may also draw wide interest—both from women who prioritize reducing their HIV risk and women with high perceived risk for unintended pregnancy, as the opening quote suggests.

MPTs are part of IPM’s mission to develop and make available new HIV prevention and sexual and reproductive health technologies for women. In addition to the one-month dapivirine ring now under regulatory review, IPM’s pipeline includes other products designed to help increase efficacy against HIV, such as a three-month dapivirine-only ring and combination products that contain multiple ARVs.

At IPM, we are working toward a world where women can thrive and reach their full potential because they have the range of products they need to protect their sexual and reproductive health. MPTs are essential to realizing that vision, because investing in women’s well-being is an investment in better health and economic outcomes for families and communities.


[1] “Women’s health.” World Health Organization, September 2013., accessed Feb. 26, 2018.

[2] UNAIDS, AIDSinfo database., accessed Feb. 26, 2018.

[3] Guttmacher Institute. “Adding It Up: Investing in Contraception and Maternal and Newborn Health, 2017.” 2017.

Additional resources:


About the Author

Crystal Ng

Crystal Ng, MPH is the senior officer for technical communications at the International Partnership for Microbicides (IPM), a nonprofit dedicated to developing new HIV prevention tools like the dapivirine ring and other sexual and reproductive health technologies for women, and making them available in developing countries. She has 12 years of experience designing, implementing, and advancing the knowledge management and monitoring & evaluation of programs working to strengthen health services, policies, and systems. 

Recent Posts

Any thoughts? Contact us to learn more about the submission process.
The IMPT is the first & only initiative dedicated to advancing the field of multipurpose prevention technologies (MPTs), products that combine HIV prevention, other STI prevention, and contraception.

IMPT Secretariat
1750 Howe Avenue, Suite 550
Sacramento, CA 95825

The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, a social impact organization dedicated to improving the health of women and their families worldwide. CAMI Health is housed at the Public Health Institute (PHI).

This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.
© Copyright 2020, Public Health Institute / CAMI Health / IMPT Secretariat. All rights reserved.